EICHOR
● Recruiting
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
Condition: Peripheral Arterial Disease · Sponsor: Eli Lilly and Company
About this study
The purpose of this study is to evaluate the effect and safety of orforglipron once daily in participants with Fontaine II peripheral arterial disease (PAD). Participation in the study will last about 58 weeks.
This description comes directly from the study's public registry record.
Talk to the study team
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 317-615-4559 · LillyTrials@Lilly.com
Physicians interested in becoming principal investigators please contact · clinical_inquiry_hub@lilly.com
Always discuss trial participation with your own doctor first.
Locations (154)
| St. Vincent's Birmingham Hospital | Birmingham, Alabama, United States | Recruiting |
| Mercy Gilbert Medical Center | Gilbert, Arizona, United States | Recruiting |
| Emvera Health at Peak Heart & Vascular Surprise | Surprise, Arizona, United States | Recruiting |
| Del Sol Research Management, LLC | Tucson, Arizona, United States | Recruiting |
| Angel City Research Inc. | Los Angeles, California, United States | Not Yet Recruiting |
| Valley Clinical Trials, LLC dba Flourish Research | Northridge, California, United States | Recruiting |
| The Cardiovascular Center | Redding, California, United States | Recruiting |
| InvivoCure | Van Nuys, California, United States | Recruiting |
| Interventional Cardiology Medical Group | West Hills, California, United States | Recruiting |
| Rocky Mountain Regional VA Medical Center | Aurora, Colorado, United States | Not Yet Recruiting |
| Lakeview Institute of Clinical Research | Leesburg, Florida, United States | Recruiting |
| Inpatient Research Clinic | Miami Lakes, Florida, United States | Recruiting |
+ 142 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07223593